New method to determine the early risk of cardiovascular disease

The risk of cardiovascular disease is closely related to the "bad" low-density lipoprotein cholesterol

Cardiovascular disease is the most common cause of death in the world and includes a variety of diseases such as stroke and myocardial infarction as well as atherosclerosis in different organs of the body

The data commonly used to assess increased heart risk is the reference value of "bad" low-density lipoprotein cholesterol

However, recent studies have shown that the importance of apolipoprotein apoA-1 is also considered, which transports "good" protective and anti-inflammatory HDL cholesterol

In this study, researchers analyzed the relationship between cardiovascular disease and apoB/apoA-1 values ​​in more than 137,000 Swedish men and women between the ages of 25 and 84

"The results show that the higher the apoB/apoA-1 value, the greater the risk of myocardial infarction, stroke, and the need for coronary artery surgery," Karolinska Institutet Senior Author and Retired Professor G ?ran Walldius said

Compared with individuals with the lowest apoB/apoA-1 values, individuals with the highest apoB/apoA-1 values ​​have a 70% higher risk of serious cardiovascular disease, and the risk of non-fatal myocardial infarction is almost three times that of the latter

This relationship is observed in both men and women, and this level of increase can be detected as early as 20 years before the onset of cardiovascular disease

"Early preventive treatment and information about cardiovascular risk are of course important for individuals to manage their risk profile," Walldius said

All in all, the researchers believe that compared with the pure apoB method, the apoB/apoA-1 ratio is a better marker for identifying more individuals at risk for future cardiovascular disease

Walldius said: "It should be possible to introduce reductions in the apoB, apoA-1, and apoB/apoA-1 ratios in the new guidelines as a supplement to the current guidelines for the detection and treatment of dyslipidemia

This research was funded by Gunner and Ingmar Jungner Experimental Medicine Foundation

references:

"Long-term risk of a major cardiovascular event (MACE) by apoB, apoA-1 and the apoB/apoA-1 ratio – experience from the Swedish AMORIS cohort: A cohort study.